HCW Biologics Inc. (HCWB)
NASDAQ: HCWB · Real-Time Price · USD
0.400
-0.001 (-0.12%)
Apr 29, 2026, 11:34 AM EDT - Market open
HCW Biologics Employees
HCW Biologics had 36 employees as of December 31, 2024. The number of employees decreased by 9 or -20.00% compared to the previous year.
Employees
36
Change (1Y)
-9
Growth (1Y)
-20.00%
Revenue / Employee
$1,506
Profits / Employee
-$619,408
Market Cap
2.69M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 36 | -9 | -20.00% |
| Dec 31, 2023 | 45 | 1 | 2.27% |
| Dec 31, 2022 | 44 | 0 | - |
| Dec 31, 2021 | 44 | 4 | 10.00% |
| Dec 31, 2020 | 40 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Calidi Biotherapeutics | 29 |
| Virax Biolabs Group | 19 |
| GeoVax Labs | 17 |
| Silexion Therapeutics | 14 |
| Azitra | 13 |
| Decoy Therapeutics | 11 |
| Ensysce Biosciences | 10 |
| Artelo Biosciences | 7 |
HCWB News
- 2 days ago - HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid Tumors - GlobeNewsWire
- 4 weeks ago - HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results - GlobeNewsWire
- 6 weeks ago - HCW Biologics Closes Exclusive Worldwide License for HCW11-006 – A High Potential Fusion Immunotherapeutic - GlobeNewsWire
- 6 weeks ago - HCW Biologics Announces Positive Research Results for CAR-T Cell Therapy Manufactured Utilizing Its Commercial-Ready Proprietary Compound, HCW9206, Published in Science Advances - GlobeNewsWire
- 2 months ago - HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter - GlobeNewsWire
- 2 months ago - HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules - GlobeNewsWire
- 2 months ago - HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune - GlobeNewsWire
- 5 months ago - HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease - GlobeNewsWire